Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Cyclophosphamide in chronic progressive multiple sclerosis: a comparative study.

L La Mantia1, M Eoli, A Salmaggi

  • 1Department of Neurology, National Neurological Institute C. Besta, Milan, Italy.

Italian Journal of Neurological Sciences
|August 10, 2000
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Novel approaches for understanding and improving the effectiveness of seed biopriming.

Scientific reports·2026
Same author

Breast density in NF1 women: a retrospective study.

Familial cancer·2024
Same author

Paracetamol (acetaminophen) rescues cognitive decline, neuroinflammation and cytoskeletal alterations in a model of post-operative cognitive decline (POCD) in middle-aged rats.

Scientific reports·2021
Same author

A case of longitudinally extensive transverse myelitis in an 80-year-old patient with systemic lupus erythematous and anti-aquaporin 4 antibodies.

Multiple sclerosis and related disorders·2021
Same author

A MIP-based low-cost electrochemical sensor for 2-furaldehyde detection in beverages.

Analytica chimica acta·2020
Same author

Bi-hemispheric transcranial direct current stimulation for upper-limb hemiparesis in acute stroke: a randomized, double-blind, sham-controlled trial.

European journal of neurology·2020
Same journal

Attualità in neurochirurgia : Edited by P. Paoletti, R. Kneich, R. Urcioli, C. Spairani Atti del XXXV Congresso Nazionale della Società Italiana di Neurochirurgia, September 1986. Mondadori Editore, 829 pages.

Italian journal of neurological sciences·2016
Same journal

24th Annual Meeting of the Italian Neuropathological Association : May 26-27-28, 1988 Napoli, Castel dell'Ovo.

Italian journal of neurological sciences·2016
Same journal

[Not Available].

Italian journal of neurological sciences·2016
Same journal

[Not Available].

Italian journal of neurological sciences·2016
Same journal

Pathogenesis and surgical treatment of neurovascular primary headaches.

Italian journal of neurological sciences·2016
Same journal

The complementary contribution of the rhinologist and the neurologist at the clinical study and treatment of the cluster headache.

Italian journal of neurological sciences·2016
See all related articles

Monthly cyclophosphamide (CFX) shows promise for progressive multiple sclerosis (MS) treatment. This study suggests monthly CFX may be safe for MS patients, but further clinical trials are needed to confirm efficacy.

Area of Science:

  • Neuroimmunology
  • Clinical Pharmacology

Background:

  • Progressive multiple sclerosis (MS) currently lacks effective treatments.
  • Cyclophosphamide (CFX), an immunosuppressive drug, has shown controversial results for MS treatment.

Purpose of the Study:

  • To evaluate the safety and clinical efficacy of three different cyclophosphamide (CFX) treatment schedules in progressive multiple sclerosis (MS) patients.

Main Methods:

  • Comparison of three CFX schedules: induction with bimonthly boosters (17 patients), bimonthly boosters alone (15 patients), and monthly boosters (21 patients) over one year.
  • Survival analysis was used to assess patient stability.
  • Adverse events including myelotoxicity and broncopneumonia were monitored.

Main Results:

Related Experiment Videos

  • Higher percentages of stable patients were observed in the induction/bimonthly boosters and monthly boosters groups.
  • Myelotoxicity was noted in the induction group, and broncopneumonia in the bimonthly boosters group.
  • The monthly boosters group (Group C) showed no major adverse effects.

    • Conclusions:

    • Monthly administration of cyclophosphamide (CFX) appears to be a potentially safe treatment option for progressive multiple sclerosis (MS).
    • Treatment response was primarily observed in patients with secondary progressive MS.
    • Further clinical trials are essential to validate the efficacy of monthly CFX in progressive MS.